SCHEMBL20340262

SCHEMBL20340262

Cc1ccc(Nc2cc(CN(CCOCCOCCN)Cc3ccccc3)nc(N)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 7/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 2/20 0.39
USP2 O75604 1/20 0.39
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 2/20 0.35
TP53 P04637 1/20 0.35
GBA1 P04062 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
AGPAT2 O15120 3/20 0.34
RXFP1 Q9HBX9 1/20 0.33
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26318080 0.93 CYP1A2 (0.40) CYP1A2CYP2D6MAPTLMNANPSR1
SCHEMBL20339039 0.78 CYP1A2 (0.49) CYP1A2CYP2D6MAPTLMNANPSR1
SCHEMBL24019191 0.77
SCHEMBL20339000 0.75 CYP1A2 (0.50) CYP1A2CYP2D6MAPTLMNANPSR1
SCHEMBL20340343 0.75 ROCK1 (0.48) CYP1A2CYP2D6MAPTNPSR1RAB9A
SCHEMBL29621922 0.75 ROCK1 (0.48) CYP1A2CYP2D6MAPTNPSR1RAB9A
SCHEMBL26318382 0.74 CYP1A2 (0.34) CYP1A2CYP2D6MAPTNPSR1RAB9A
SCHEMBL20340271 0.73 CYP1A2 (0.50) CYP1A2CYP2D6MAPTLMNANPSR1
SCHEMBL22498765 0.73 CARM1 (0.46) HTTSMN1; SMN2
SCHEMBL20340282 0.73 RAB9A (0.44) CYP1A2CYP2D6MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
EP-3562811-B1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S L (ES) 2022-03-16 EP disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2019-11-07 US disclosed
EP-3562811-A1 HETEROARYL COMPOUNDS AND THEIR USE Minoryx Therapeutics S.L. (ES) 2019-11-06 EP disclosed
WO-2018122775-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2018-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA CYP1A2 815/4885CYP2D6 892/4885MAPT 229/4885
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA CYP1A2 815/4885CYP2D6 892/4885MAPT 229/4885
US-11174242-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA CYP1A2 815/4885CYP2D6 892/4885MAPT 229/4885
US-11739072-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA CYP1A2 815/4885CYP2D6 892/4885MAPT 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.